Table 3.
Effect of embolic agent on inflammatory markers and hormonal assays
| Embospheres | Gelfoam | Difference between groups (E-G) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baselinea | 6 monthsa | Changeb | p | Baselinea | 6 monthsa | Changeb | p | Differencec | p | |
| WCC1 | 5.9 (2.2) | 6.5 (1.8) | 0.6 (−0.2 to 1.4) | 0.11 | 6.4 (3.7) | 6.3 (1.0) | −0.1 (−2.9 to 2.5) | 0.90 | 0.4 (−0.9 to 1.7) | 0.56 |
| CRP2 | 1.4 (0.8) | 2.1 (2.5) | 0.9 (−0.7 to 2.5) | 0.24 | 2.8 (2.6) | 1.4 (1.0) | −1.3 (−2.6 to 0.1) | 0.06 | 1.5 (−0.4 to 3.5) | 0.12 |
| LH3 | 8.0 (10.1) | 11.5 (9.7) | 3.5 (−2.6 to 9.6) | 0.23 | 7.5 (9.4) | 12.5 (15.9) | 5.0 (−0.3 to 10.3) | 0.06 | −1.5 (−9.2 to 6.2) | 0.68 |
| FSH4 | 11.7 (13.3) | 13.9 (12.6) | 2.2 (−4.2 to 8.5) | 0.46 | 11.5 (12.6) | 21.4 (27.5) | 9.9 (−3.2 to 23.0) | 0.12 | −7.7 (−21.4 to 5.8) | 0.25 |
| 5E2d | 135.5 (107.8308.0) | 226.0 (73.3370.8) | d | d | 213.0 (80.0,309.3) | 129.5 (70.0,315.0) | d | d | d | d |
| 6AMHd | 4.0 (4.0,4.6) | 4.0 (4.0,4.0) | d | d | 4.0 (4.0,4.0) | 4.0 (4.0,4.0) | d | d | d | d |
aMean (SD)
bMean of change over time calculated as 6 month – baseline, 95% CI of change
cMean difference between embolic agents at 6 months adjusted for baseline values, 95% CI of difference. Positive values indicate higher results in the E group
dMedian (inter-quartile range). No analyses carried out for AMH and E2 due to large numbers of results recorded as `below limit of detection’
1Normal range for WCC is 4–11 × 109/L. 2Normal CRP is less than 10 mg/L. 3, 4Normal range in pre-menopausal women for LH is 5 to 25 IU/L and FSH is 4.7–21.5 IU/L. 5Normal range for Estradiol (E2) in follicular phase is 77–920 pmol/L, mid cycle is 140–2380 pmol/L and luteal phase is 77–1145 pmol/L. 6Normal range in pre-menopausal women for AMH < 50 pmol/L